Myriad Genetics (MYGN) Other Non-Current Liabilities (2010 - 2026)

Myriad Genetics has disclosed Other Non-Current Liabilities across 17 years of filings, most recently posting $1.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 15.0% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 15.0% YoY), while the FY2025 annual figure was $1.9 million, down 13.64% from the prior year.
• Other Non-Current Liabilities slipped to $1.7 million in Q1 2026, from $1.9 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for MYGN reached as high as $48.1 million in Q4 2023 and fell as low as $1.7 million in Q3 2025.
• The 5-year median for Other Non-Current Liabilities is $11.5 million (2023), against an average of $19.8 million.
• The widest YoY moves for Other Non-Current Liabilities: up 253.04% in 2024, down 95.43% in 2024.
• A 5-year view of Other Non-Current Liabilities shows it stood at $43.9 million in 2022, then advanced by 9.57% to $48.1 million in 2023, then tumbled by 95.43% to $2.2 million in 2024, then retreated by 13.64% to $1.9 million in 2025, then decreased by 10.53% to $1.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.7 million, $1.9 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.